[HTML][HTML] Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: stratification by maternal and …
M Korjagina, KM Hakkarainen, S Burkill… - Multiple sclerosis and …, 2021 - Elsevier
Background Previous studies reported no increase in the prevalence of adverse pregnancy
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn …
M Korjagina, KM Hakkarainen, S Burkill… - Multiple Sclerosis and …, 2020 - europepmc.org
Background Previous studies reported no increase in the prevalence of adverse pregnancy
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn …
NMSPI Be, M Korjagina, KM Hakkarainen, S Burkill… - 2021 - helda.helsinki.fi
Background: Previous studies reported no increase in the prevalence of adverse pregnancy
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn …
M Korjagina, KM Hakkarainen… - Multiple sclerosis …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Previous studies reported no increase in the prevalence of adverse pregnancy
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
[HTML][HTML] Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and …
M Korjagina, KM Hakkarainen, S Burkill… - Multiple Sclerosis …, 2021 - msard-journal.com
Background Previous studies reported no increase in the prevalence of adverse pregnancy
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn …
M Korjagina, KM Hakkarainen, S Burkill… - Multiple Sclerosis and …, 2020 - diva-portal.org
BACKGROUND: Previous studies reported no increase in the prevalence of adverse
pregnancy outcomes after exposure to interferon-beta (IFN-beta). However, no study has …
pregnancy outcomes after exposure to interferon-beta (IFN-beta). However, no study has …
[PDF][PDF] Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and …
NMSPI Be, M Korjagina… - Multiple sclerosis …, 2021 - researchportal.helsinki.fi
Background: Previous studies reported no increase in the prevalence of adverse pregnancy
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …